KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $96000.0.

  • TherapeuticsMD's Depreciation & Amortization (CF) changed 0.0% to $96000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387000.0, marking a year-over-year decrease of 6300.19%. This contributed to the annual value of $509000.0 for FY2024, which is 4479.39% down from last year.
  • Per TherapeuticsMD's latest filing, its Depreciation & Amortization (CF) stood at $96000.0 for Q3 2025, which was down 0.0% from $96000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Depreciation & Amortization (CF) registered a high of $1.0 million during Q2 2021, and its lowest value of -$2.4 million during Q4 2021.
  • Over the past 5 years, TherapeuticsMD's median Depreciation & Amortization (CF) value was $133000.0 (recorded in 2024), while the average stood at $192000.0.
  • In the last 5 years, TherapeuticsMD's Depreciation & Amortization (CF) crashed by 32908.56% in 2021 and then surged by 39259.26% in 2024.
  • TherapeuticsMD's Depreciation & Amortization (CF) (Quarter) stood at -$2.4 million in 2021, then skyrocketed by 113.12% to $309000.0 in 2022, then surged by 106.15% to $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then dropped by 4.0% to $96000.0 in 2025.
  • Its last three reported values are $96000.0 in Q3 2025, $96000.0 for Q2 2025, and $95000.0 during Q1 2025.